Fenwick & West represented Invenra Inc. in its expanded collaboration with Exelixis, Inc. (Nasdaq: EXEL). Exelixis and Invenra had entered into a collaboration on May 2, 2018, to discover and develop multispecific antibodies through the use of Invenra’s B-BodyTMtechnology platform. The new collaboration will continue to use the Invenra antibody discovery capabilities to generate additional biologics-based programs.
More information about the collaboration can be obtained from Invenra’s announcement.
The Fenwick transaction team included technology transactions partner Stefano Quintini and licensing attorney Amy Manning.